ImmunoACT

Executive Summary

ImmunoACT is an Indian cell-and-gene therapy company focused on developing and manufacturing affordable autologous CAR-T cell therapies for B-cell malignancies. Its lead product, NexCAR19 (talicabtagene autoleucel), is approved in India for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). Leveraging a proprietary lentiviral platform and a GMP-certified facility in Mumbai, the company aims to reduce the cost of CAR-T therapy, making it accessible in India and other emerging markets. As a commercial-stage private company, ImmunoACT is positioned to address the significant unmet need for affordable cell therapies in low- and middle-income countries. With a growing pipeline and a focus on operational efficiency, the company is a key player in the global cell therapy landscape.

Upcoming Catalysts (preview)

• Q2 2027Expansion of NexCAR19 approvals to additional countries in Asia and Africa70% success
• Q1 2027Initiation of pivotal trial for NexCAR19 in new indications (e.g., multiple myeloma or solid tumors)60% success
• Q4 2026Strategic partnership or licensing deal for global manufacturing and commercialization50% success